CPRX · As filed with the SEC
Catalyst Pharmaceuticals cash flow statement, by quarter
The statement as Catalyst Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS · USD
| USD | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025† 3 months ended Dec 31, 2025 | Q3 2025† 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 |
|---|---|---|---|---|
| Operating Activities: | ||||
| Net income | 63,734,000 | — | — | — |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | ||||
| Depreciation | 70,000 | — | — | — |
| Stock-based compensation | 6,260,000 | — | — | — |
| Amortization of intangible assets | 9,703,000 | — | — | — |
| Deferred taxes | (2,336,000) | — | — | — |
| Accretion of discount | (135,000) | — | — | — |
| Reduction in the carrying amount of right-of-use asset | 77,000 | — | — | — |
| Change in fair value of equity securities | (4,750,000) | — | — | — |
| Inventory reserve and write-offs | — | 83,000† | (292,000)† | — |
| (Increase) decrease in: | ||||
| Accounts receivable, net | (4,357,000) | — | — | — |
| Inventory | 2,236,000 | — | — | — |
| Prepaid expenses and other current assets | 2,449,000 | — | — | — |
| Increase (decrease) in: | ||||
| Accounts payable | (4,051,000) | — | — | — |
| Accrued expenses and other liabilities | (9,207,000) | — | — | — |
| Operating lease liability | (106,000) | — | — | — |
| Net cash provided by (used in) operating activities | 59,587,000 | — | — | — |
| Investing Activities: | ||||
| Purchases of property and equipment | (27,000) | — | — | — |
| Net cash provided by (used in) investing activities | (27,000) | — | — | — |
| Financing Activities: | ||||
| Payment of employee withholding tax related to stock-based compensation | (301,000) | — | — | — |
| Proceeds from exercise of stock options | 3,302,000 | — | — | — |
| Repurchase of common stock | (14,574,000) | — | — | — |
| Payment of liabilities arising from asset acquisition | (1,299,000) | — | — | — |
| Net cash provided by (used in) financing activities | (12,872,000) | — | — | — |
| Net increase (decrease) in cash and cash equivalents | 46,688,000 | — | — | — |
| Cash and cash equivalents – beginning of period | 709,171,000 | 689,892,000 | 652,800,000 | 580,656,000 |
| Cash and cash equivalents – end of period | 755,859,000 | 709,171,000 | 689,892,000 | 652,800,000 |
| Supplemental disclosures of cash flow information: | ||||
| Cash paid for income taxes | 1,839,000 | — | — | — |
| Cash paid for interest | 140,000 | — | — | — |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.